Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.

Verona Pharma (VRNA) has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement and ...

Capital, Aurora Capital and Platinum Equity are among the PE firms investing in the pharma packaging and storage services ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor ...